Massachusetts General Hospital
The study evaluates the effect of theophylline in 100 subjects with Pseudohypoparathyroidism.
It is an open label intervention study for the off-label use of theophylline in psuedohypoparathyroidism (PHP).Theophylline is a is non-specific phosphodiesterase inhibitor which increases the levels of secondary messenger,cAMP. PHP patients have end organ resistance to hormones involving cAMP signaling. Thus, theophylline has a potential to abrogate hormone resistance. Also, it may have a role in bone maturation, neurocognition and metabolism.
Inclusion Criteria: * Subjects with known diagnosis of PHP1A and PHP1B * Age \>5 years Exclusion Criteria: * • Significant kidney disease, i.e. any CKD stage * Hypercalciuria * Kidney stones * Severe Heart disease * Uncontrolled seizure disorder * Peptic ulcer * Liver dysfunction * Bleeding disorder * Allergy to theophylline preparation * Muscle disorder * Infection * Any neurologic disease * Chronic drugs interacting with theophylline
Theophylline will be given to maintain a peak level between 10-15 mcg/mL
Arctuva estimate
Verify or correct the compensation shown for this listing.